Table 3.
Clinical response to ibrutinib and buparlisib combination in 37 patients, of whom 35 were evaluable for response
| Total (N=37) |
MCL (n=18) |
FL (n=5) |
DLBCL (n=14) |
|
|---|---|---|---|---|
| Evaluable for overall response | 35 | 17 | 5 | 13 |
| Best response by Lugano criteria, n (%) | ||||
| Overall response | 21 (60) | 16 (94) | 1 (20) | 4 (31) |
| Complete response | 17 (49) | 13 (76) | 1 (20) | 3 (23) |
| Partial response | 4 (11) | 3 (18) | - | 1 (8) |
| Stable disease | 4 (11) | - | 4 (80) | - |
| Progressive disease | 11 (31) | 1 (6) | - | 10 (77) |
| Treatment duration, weeks, median (range)b | 16 (1–146) | 39 (1–146) | 16 (8–79) | 7 (2–145) |
a
The 2 patients not evaluable for overall response were 1 patient with MCL who was off treatment for toxicity prior to response assessment and 1 patient with DLBCL who had a sudden death not attributed to treatment without formal radiographic assessment.
b
Ongoing as of March 31, 2021.